Open AccessPrognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia
Author(s) -
Susan O’Brien,
Samantha Jaglowski,
John C. Byrd,
Rajat Bannerji,
Kristie A. Blum,
Christopher P. Fox,
Richard R. Furman,
Peter Hillmen,
Thomas J. Kipps,
Marco Montillo,
Jeff P. Sharman,
Sam Suzuki,
Danelle F. James,
Alvina D. Chu,
Steven Coutré
Publication year - 2018
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2017.5604
Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , bendamustine , univariate analysis , oncology , leukemia , multivariate analysis
Ibrutinib, a first-in-class Bruton tyrosine kinase inhibitor taken once daily, is approved in the United States for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and allows for treatment without chemotherapy. Extended treatment with ibrutinib has demonstrated increased complete response (CR) rates over time.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom